MDR Rule 13: Why Most Active Devices Default to Class I

Annex VIII of Regulation (EU) 2017/745 groups active-device classification into five rules, Rule 9 through Rule 13. The first four push devices upward — toward IIa, IIb, or III — based on what the device does to the body: exchange therapeutic energy, diagnose or monitor, run as software, or administer and remove substances. Rule 13 is what is left over: all other active devices, classified as Class I. Teams that see “active” and reach for a higher class before checking whether Rules 9 through 12 actually apply are over-classifying devices that MDR itself puts in the self-certification tier.

How the active-device rules actually divide up

Rules 9 through 12 are specific, not general. Rule 9 covers active therapeutic devices intended to administer or exchange energy with the body, defaulting to Class IIa unless that exchange happens in a potentially hazardous way, which pushes it to IIb — see the Rule 9 energy test in more depth. Rule 10 covers active devices for diagnosis and monitoring, in more depth than a catch-all article needs — see the Rule 10 immediate-danger test. Rule 11 covers software, already its own well-trodden ground on this site in the Rule 11 classification analysis. Rule 12 covers active devices that administer or remove medicinal products, body fluids, or other substances — IIa by default, IIb where the manner of administration or removal is potentially hazardous. A device has to actually do one of those four things to be classified under one of those four rules.

Where the over-classification mistake happens

The failure mode we see is a team treating “active” as shorthand for “at least IIa,” because every other active rule on the page pushes upward. That intuition is backwards for anything that doesn't fit Rules 9 through 12. An examination lamp, a height-adjustable treatment table, or a general-purpose active support device with no therapeutic, diagnostic, software, or substance-delivery function has nowhere else in Annex VIII's active-device section to land — Rule 13 is the correct answer, and Class I is the correct class, self-certified under the manufacturer's own EU regulatory strategy rather than routed to a notified body it was never going to need.

• Run the rule-out, not just the rule-in. Confirm the device fails Rules 9, 10, 11, and 12 in turn before defaulting to Rule 13 — the documentation should show the elimination, not just the conclusion.
• Don't let 'active' do the classifying. The presence of a power source is a precondition for Rules 9-13 applying at all, not a reason to pick a higher one among them.
• Watch the borderline with Rule 12. A device that both positions a patient and administers a substance may trip Rule 12 instead of Rule 13 — the substance-handling function controls.
• Treat Rule 13 as a conclusion to document, not skip. A thin classification rationale on a Class I device is exactly what a notified body or competent authority questions first during a later scope review.

Rule 13 is not a loophole. It is what MDR's own active-device logic produces when a device genuinely doesn't do any of the four things the earlier rules are built around. Why the Class I conclusion still needs a rationale

The exception that pulls some devices back out

Rule 13's default is not absolute for one specific population: active products with no intended medical purpose that fall under MDR's Annex XVI common specifications. Those products are brought under MDR by analogy to Annex VIII's rules, but because they have no medical purpose, Rules 9 and 10 — which both key off a diagnostic or therapeutic intent — frequently cannot apply to them, leaving Rule 13's Class I default as the fallback. The European Commission closed part of that gap with Commission Implementing Regulation (EU) 2022/2347, which names specific Annex XVI product groups, equipment used for aesthetic and other non-medical purposes, and assigns them a class above Rule 13's default by regulation rather than by the rule's own logic. If your device has no intended medical purpose, check Annex XVI and that regulation before relying on Rule 13 at all; if it has a genuine medical purpose and simply doesn't fit Rules 9 through 12, Rule 13 applies as written.

None of this is exotic, but it is easy to skip under deadline pressure, because the active-device rules read as a ladder that only goes up. Rule 13 is the rung at the bottom, and it exists because MDR's own logic says some active devices belong there. The manufacturers who get this wrong tend to either over-classify a Class I device into an unnecessary notified-body relationship, or under-classify an Annex XVI product that Reg. 2022/2347 has already named at a higher tier. Both mistakes come from skipping the rule-out step Rule 13 actually requires.